This study focuses on patients with Hemophagocytic lymphohistiocytosis, a rare and serious condition where the immune system becomes overactive and causes excessive inflammation. This inflammation can lead to organ failure, which occurs when vital organs like the liver, kidneys, or lungs stop working correctly. The study is being conducted to compare two different ways of starting a treatment called etoposide in patients who are receiving intensive care. All patients in the study also receive dexamethasone, a medication used to reduce inflammation.

The first group will receive etoposide very early, within 12 hours of being admitted to the study. The second group will follow a delayed strategy, where the medication is only started if the patient’s condition does not improve after 48 hours. During the course of the study, researchers will monitor how these different timing strategies affect the development or worsening of organ problems. The study will also look at various aspects of recovery, such as the length of time spent in the hospital and the need for support from machines like a ventilator, which helps a person breathe.